NeuroBo Pharmaceuticals, Inc.'s stock (NRBO) experienced a significant increase of 48 percent on Thursday. This surge followed the FDA's approval of the company's application for an Investigational New Drug, named DA-1726. This new drug is referred to as a dual oxyntomodulin analog agonist.
NeuroBo's stock showed a substantial climb of 48.31 percent, going up to $4.85 from its last closing figure of $3.27. This is based on a volume of 24,262,634. Previously, the stock traded between $2.89 and $7.60 over the past 52-week period on the Nasdaq.
The company anticipates that DA-1726 will function as a glucagon-like peptide-1 receptor and glucagon receptor.
